NASDAQ:LOGC LogicBio Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.40 +0.05 (+14.43%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.35▼$0.4150-Day Range$0.35▼$0.6752-Week Range$0.34▼$5.15Volume303,752 shsAverage Volume830,212 shsMarket Capitalization$13.07 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability LogicBio Therapeutics Stock Forecast (MarketRank)Analyst RatingModerate Buy2.75 Rating ScoreUpside/Downside2,369.1% Upside$10.00 Price TargetShort InterestHealthy0.76% of Float Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.04) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.22 out of 5 starsMedical Sector785th out of 1,429 stocksBiological Products, Except Diagnostic Industry126th out of 217 stocks 3.4 Analyst's Opinion Consensus RatingLogicBio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, LogicBio Therapeutics has a forecasted upside of 2,369.1% from its current price of $0.41.Amount of Analyst CoverageLogicBio Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.76% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LogicBio Therapeutics has recently decreased by 37.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLogicBio Therapeutics has received a 74.40% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Basic medical research services" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for LogicBio Therapeutics is -0.49. Previous Next 3.0 News and Social Media Coverage News SentimentLogicBio Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for LogicBio Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -93% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of LogicBio Therapeutics is held by insiders.Percentage Held by Institutions55.20% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LogicBio Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About LogicBio Therapeutics (NASDAQ:LOGC)LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More LOGC Stock News HeadlinesJune 14, 2022 | morningstar.comLogicBio Therapeutics Inc - Stock Quote LOGCMay 17, 2022 | finance.yahoo.comLogicBio® Therapeutics to Present at H.C. Wainwright Global Investment ConferenceMay 16, 2022 | finance.yahoo.comLogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business UpdatesMay 11, 2022 | finance.yahoo.comLogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual MeetingMay 9, 2022 | uk.investing.comWhy LogicBio Therapeutics Shares Are Popping Off TodayMay 9, 2022 | markets.businessinsider.comLogicBio Says FDA Lifts Clinical Hold On LB-001 INDMay 9, 2022 | markets.businessinsider.comClinical Development Update from Portfolio Company LogicBioMay 9, 2022 | seekingalpha.comLogicBio surges as FDA lifts clinical hold on lead assetMay 9, 2022 | finance.yahoo.comLogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic AcidemiaMay 9, 2022 | finance.yahoo.comLogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric TrialApril 27, 2022 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.38%March 23, 2022 | finance.yahoo.comLogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing ConferenceMarch 12, 2022 | benzinga.comLogicBio Therapeutics's Return On Capital Employed InsightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LOGC CUSIPN/A CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/01/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+2,422.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.120010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40.03 million Net Margins-468.89% Pretax Margin-469.25% Return on Equity-104.61% Return on Assets-55.86% Debt Debt-to-Equity Ratio0.17 Current Ratio2.74 Quick Ratio2.74 Sales & Book Value Annual Sales$5.41 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.43Miscellaneous Outstanding Shares32,963,000Free Float30,722,000Market Cap$13.07 million OptionableNot Optionable Beta1.49 LogicBio Therapeutics Frequently Asked Questions Should I buy or sell LogicBio Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LogicBio Therapeutics stock. View analyst ratings for LogicBio Therapeutics or view top-rated stocks. What is LogicBio Therapeutics' stock price forecast for 2022? 4 brokers have issued 1 year target prices for LogicBio Therapeutics' stock. Their LOGC stock forecasts range from $6.00 to $16.00. On average, they predict LogicBio Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 2,422.1% from the stock's current price. View analysts' price targets for LogicBio Therapeutics or view top-rated stocks among Wall Street analysts. How has LogicBio Therapeutics' stock performed in 2022? LogicBio Therapeutics' stock was trading at $2.31 at the beginning of 2022. Since then, LOGC stock has decreased by 82.8% and is now trading at $0.3965. View the best growth stocks for 2022 here. When is LogicBio Therapeutics' next earnings date? LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for LogicBio Therapeutics. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.06. The firm had revenue of $2.82 million for the quarter. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 104.61% and a negative net margin of 468.89%. View LogicBio Therapeutics' earnings history. Who are LogicBio Therapeutics' key executives? LogicBio Therapeutics' management team includes the following people: Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 55, Pay $793.2k) (LinkedIn Profile)Dr. Mark A. Kay M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 64, Pay $107.5k)Ms. Cecilia Jones, CFO & Treasurer (Age 47, Pay $531.09k)Dr. Daniel J. Gruskin M.D., Chief Medical Officer (Age 50, Pay $577.48k)Dr. Leszek Lisowski M.B.A., Ph.D., Co-Founder & Member of Scientific Advisory BoardDr. Adi Barzel Ph.D., Co-FounderDr. Matthias Hebben Ph.D., Global VP & Head of Technology Devel.Ms. Mariana Nacht Ph.D., Chief Scientific Officer (Age 58)Ms. Andrea Paul, Gen. Counsel & Corp. Sec. (Age 41)Ms. Grace Lochhead, VP & Head of HR Who are some of LogicBio Therapeutics' key competitors? Some companies that are related to LogicBio Therapeutics include Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Cognition Therapeutics (CGTX), OKYO Pharma (OKYO), MiNK Therapeutics (INKT), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Senti Biosciences (SNTI), Xtant Medical (XTNT), IN8bio (INAB), Pluristem Therapeutics (PSTI), AVROBIO (AVRO), TRACON Pharmaceuticals (TCON), Applied Genetic Technologies (AGTC) and CASI Pharmaceuticals (CASI). View all of LOGC's competitors. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI). When did LogicBio Therapeutics IPO? (LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager. What is LogicBio Therapeutics' stock symbol? LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC." How do I buy shares of LogicBio Therapeutics? Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LogicBio Therapeutics' stock price today? One share of LOGC stock can currently be purchased for approximately $0.40. How much money does LogicBio Therapeutics make? LogicBio Therapeutics (NASDAQ:LOGC) has a market capitalization of $13.07 million and generates $5.41 million in revenue each year. The company earns $-40.03 million in net income (profit) each year or ($1.120010) on an earnings per share basis. How many employees does LogicBio Therapeutics have? LogicBio Therapeutics employs 62 workers across the globe. How can I contact LogicBio Therapeutics? LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The official website for LogicBio Therapeutics is www.logicbio.com. The company can be reached via phone at (617) 245-0399 or via email at [email protected]. This page (NASDAQ:LOGC) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
